Angioblast Systems, Inc. is a private New York City-based biotechnology company committed to the development of novel treatments for cardiac, vascular, and eye conditions.

Angioblast's lead products are based on commercialisation of a unique adult stem cell technology using adult Mesenchymal Precursor Cells, capable of regulating blood vessel growth critical for the treatment of ischemic heart disease and macular degeneration/diabetic eye disease.

Angioblast's focus is to progress through clinical trials and regulatory processes necessary to commercialise the technology in as short a timeframe as possible.

Mesoblast has acquired 39.2% equity in Angioblast.

www.angioblast.com

About us
Organisation
Executive management
Scientific Advisory Board
Corporate Governance